Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

Executives Sell More Than $262M Of 5 Stocks

Although gold futures traded higher on Monday, there were a few notable insider trades.

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.

Investors Business Daily

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Falls; Oil Prices Dive As U.S. Eyes Reserve Release

The Dow Jones Industrial Average fell Thursday. Oil prices dived on news that the Biden administration is planning to tap U.S. oil reserves.

Investors Business Daily

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.

Investors Business Daily

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview For Regeneron Pharmaceuticals

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Analyst Ratings For Regeneron Pharmaceuticals

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

IBD MarketSmith

Arista Networks

IBD Leaderboard

Vertex Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

305,640 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play